111In-Nd2

111In-Nd2 is a radiolabeled monoclonal antibody preparation in which the c-Nd2 antibody is conjugated with the radioisotope indium-111. The antibody portion (c-Nd2) targets antigens expressed on certain cancer cells. Indium-111 is a gamma-emitting radionuclide that enables imaging via radioimmunodetection (RAID), facilitating the preoperative diagnosis and localization of cancers, particularly distinguishing invasive pancreatic cancer from other pancreatic masses. This agent is designed for use in nuclear medicine, where the antibody delivers the radioactive payload specifically to tumor sites, enhancing tumor visualization for diagnostic purposes via SPECT or planar scintigraphy. The mechanism of action is highly dependent on the antibody's target specificity, with the radioisotope enabling sensitive detection through accumulation at the site of antigen expression[7].

Other names

111In-labeled c-Nd2